4.8 Article

Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling

期刊

BMC BIOLOGY
卷 19, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12915-021-00979-5

关键词

High-throughput screen; Mitochondria; Luteolin; Mitochondria-ER contacts; Mitochondrial calcium

类别

资金

  1. EU Joint Programme -Neurodegenerative Disease Research (JPND)
  2. Swedish Research Council [2018-03102]
  3. Swedish Brain Foundation (Hjarnfonden)
  4. Swedish Alzheimer Foundation (Alzheimerfonden)
  5. European Union [676144]
  6. Gun och Bertil Stohnes Foundation (Stockholm)
  7. Olle Engkvist Foundation (Stockholm)
  8. Hallstens forskningsstiftelse
  9. Hjarnfonden
  10. Alzheimerfonden
  11. University of Padova, Italy (SID 2019)
  12. Italian Ministry of University and Scientific Research [PRIN2017XA5J5N]
  13. Fondazione Cassa di Risparmio di Padua e Rovigo (CARIPARO Foundation) Excellence project 2017 [2018/113]
  14. UNIPD Funds for Research Equipment-2015
  15. Euro Bioimaging Project Roadmap/ESFRI from European Commission
  16. Science Foundation Ireland [14/JPND/B3077]
  17. Science Foundation Ireland (SFI FutureNeuro Research Centre) [16/RC/3948]
  18. Science Foundation Ireland (European Regional Development Fund)
  19. Science Foundation Ireland (FutureNeuro)
  20. Karolinska Institute
  21. Gamla Tjanarinnor Foundation (Stockholm)
  22. Swedish Research Council [2018-03102] Funding Source: Swedish Research Council

向作者/读者索取更多资源

This study established a large-scale screening platform for mitochondrial-based modulators and identified luteolin as a compound with potential therapeutic validity for various human diseases by increasing mitochondrial activity through enhancing interactions between mitochondria and endoplasmic reticulum. The findings suggest a novel mechanism for luteolin's modulation of mitochondrial function in neuronal models and potential therapeutic applications.
Background Mitochondrial dysfunction is a common feature of aging, neurodegeneration, and metabolic diseases. Hence, mitotherapeutics may be valuable disease modifiers for a large number of conditions. In this study, we have set up a large-scale screening platform for mitochondrial-based modulators with promising therapeutic potential. Results Using differentiated human neuroblastoma cells, we screened 1200 FDA-approved compounds and identified 61 molecules that significantly increased cellular ATP without any cytotoxic effect. Following dose response curve-dependent selection, we identified the flavonoid luteolin as a primary hit. Further validation in neuronal models indicated that luteolin increased mitochondrial respiration in primary neurons, despite not affecting mitochondrial mass, structure, or mitochondria-derived reactive oxygen species. However, we found that luteolin increased contacts between mitochondria and endoplasmic reticulum (ER), contributing to increased mitochondrial calcium (Ca2+) and Ca2+-dependent pyruvate dehydrogenase activity. This signaling pathway likely contributed to the observed effect of luteolin on enhanced mitochondrial complexes I and II activities. Importantly, we observed that increased mitochondrial functions were dependent on the activity of ER Ca2+-releasing channels inositol 1,4,5-trisphosphate receptors (IP(3)Rs) both in neurons and in isolated synaptosomes. Additionally, luteolin treatment improved mitochondrial and locomotory activities in primary neurons and Caenorhabditis elegans expressing an expanded polyglutamine tract of the huntingtin protein. Conclusion We provide a new screening platform for drug discovery validated in vitro and ex vivo. In addition, we describe a novel mechanism through which luteolin modulates mitochondrial activity in neuronal models with potential therapeutic validity for treatment of a variety of human diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据